Importantly, GPR17 has been shown to “promiscuously” respond to several different proinflammatory ligands accumulating at injury sites (Sensi et al., 2014; Parravicini et al., 2016), not only uracil nucleotides and cysteinyl‐leukotrienes (Ciana et al., 2006), but also oxysterols and CXCL12 (Parravicini et al., 2016), one of the most prominent chemokines in the lesions of multiple sclerosis patients (Calderon et al., 2006). The gene discussed is GPR17; the disease is multiple sclerosis.